Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer

被引：1

作者：

Hotta, Katsuyuki ^{[1
]}

Kiura, Katsuyuki ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Resp Med, Kita Ku, Okayama 7008558, Japan

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2011年 / 11卷 / 07期

关键词：

elrotinib; non-small-cell lung cancer; toxicity; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; PREVIOUSLY TREATED PATIENTS; JAPANESE PATIENTS; CLINICAL-SIGNIFICANCE; PRACTICAL MANAGEMENT; EGFR MUTATIONS; GENE-MUTATIONS; SKIN RASH;

D O I：

10.1586/ERA.11.74

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Erlotinib is an orally available, small-molecule EGF receptor tyrosine kinase inhibitor. It has shown promising activity in chemotherapy-relapsed patients with advanced non-small-cell lung cancer and is now approved in many countries. To date, there have been a number of clinical studies of erlotinib therapy demonstrating its safety as well as its efficacy. This article summarizes clinical study results in advanced non-small-cell lung cancer, so that we can comprehensively understand the toxicities expected with erlotinib in non-small-cell lung cancer patients.

引用

页码：991 / 997

页数：7

共 57 条

[1]

Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[2] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[3] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[4] Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib [J].

Cataldo, Vince D. ;

Gibbons, Don L. ;

Perez-Soler, Roman ;

Quintas-Cardama, Alfonso .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (10) :947-955

[5] AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation [J].

Chan, TO ;

Rittenhouse, SE ;

Tsichlis, PN .

ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :965-1014

[6]

Ciardiello F, 2001, CLIN CANCER RES, V7, P2958

[7] FDA drug approval summary:: Erlotinib (Tarceva®) tablets [J].

Cohen, MH ;

Johnson, JR ;

Chen, YF ;

Sridhara, R ;

Pazdur, R .

ONCOLOGIST, 2005, 10 (07) :461-466

[8] Practical management of patients with chronic myeloid leukemia receiving imatinib [J].

Deininger, MWN ;

O'Brien, SG ;

Ford, JM ;

Druker, BJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1637-1647

[9]

Demetri George D, 2007, J Natl Compr Canc Netw, V5 Suppl 2, pS1

[10] EFFECTS OF EGF, BFGF, NGF AND PDGF(BB) ON CELL PROLIFERATIVE, MIGRATORY AND INVASIVE CAPACITIES OF HUMAN BRAIN-TUMOR BIOPSIES INVITRO [J].

ENGEBRAATEN, O ;

BJERKVIG, R ;

PEDERSEN, PH ;

LAERUM, OD .

INTERNATIONAL JOURNAL OF CANCER, 1993, 53 (02) :209-214

← 1 2 3 4 5 6 →